Organization Profile

You just read:

Health Canada approves REVLIMID® plus dexamethasone as a first-line treatment for patients newly diagnosed with multiple myeloma, not eligible for transplant

News provided by

Celgene Inc.

Jan 24, 2017, 08:00 ET